Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous syst...
Aarti Pharmalabs reported revenue of 20.86 billion INR for fiscal year 2025, up 14.9% from fiscal year 2024, and net income of 2.72 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 4.32 billion INR, down 19.6% from a year before. Outside India was its largest region in fiscal year 2025, with 58% of revenue. Its market capitalization was 79.65 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.